413 related articles for article (PubMed ID: 26156260)
1. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
Yan LZ; Herrington JD
J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
3. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.
Chatzinikolaou I; Abi-Said D; Bodey GP; Rolston KV; Tarrand JJ; Samonis G
Arch Intern Med; 2000 Feb; 160(4):501-9. PubMed ID: 10695690
[TBL] [Abstract][Full Text] [Related]
4. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia.
Geletko SM; Melbourne KM; Mikolich DJ
Ann Pharmacother; 1996 Mar; 30(3):246-8. PubMed ID: 8833559
[TBL] [Abstract][Full Text] [Related]
6. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer.
Zhang S; Wang Q; Ling Y; Hu X
BMC Cancer; 2015 Feb; 15():42. PubMed ID: 25763661
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
[TBL] [Abstract][Full Text] [Related]
9. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies.
Todeschini G; Franchini M; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Murari C; Ricetti MM; Perona G
Int J Infect Dis; 1998-1999 Winter; 3(2):99-104. PubMed ID: 10225988
[TBL] [Abstract][Full Text] [Related]
10. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Nguyen AD; Heil EL; Patel NK; Duffy A; Gilmore S
J Oncol Pharm Pract; 2016 Apr; 22(2):303-7. PubMed ID: 25567517
[TBL] [Abstract][Full Text] [Related]
11. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
[TBL] [Abstract][Full Text] [Related]
12. Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia.
Kleinhendler E; Cohen MJ; Moses AE; Paltiel O; Strahilevitz J; Cahan A
Int J Antimicrob Agents; 2018 Jan; 51(1):71-76. PubMed ID: 28705670
[TBL] [Abstract][Full Text] [Related]
13. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
14. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.
Scheetz MH; Bolon MK; Scarsi KK; Fotis MA; Postelnick MJ
J Infect; 2006 Feb; 52(2):105-10. PubMed ID: 15904961
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
17. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.
Nguyen LH; Hsu DI; Ganapathy V; Shriner K; Wong-Beringer A
J Antimicrob Chemother; 2008 Mar; 61(3):714-20. PubMed ID: 18222951
[TBL] [Abstract][Full Text] [Related]
18. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of bacteremia in febrile neutropenic episodes in children with cancer: microbiologic and molecular approach.
Santolaya ME; Farfán MJ; De La Maza V; Cociña M; Santelices F; Alvarez AM; Avilés CL; Becker A; O'Ryan M; Román P; Salgado C; Silva P; Topelberg S; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M; Torres JP
Pediatr Infect Dis J; 2011 Nov; 30(11):957-61. PubMed ID: 21768922
[TBL] [Abstract][Full Text] [Related]
20. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.
Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I
Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
